Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that it has commenced a new European study of Oral-lyn, the Company's proprietary oral insulin spray product, in patients with Type-1 diabetes mellitus. The study, entitled "A 12-Week, Open-Label, Randomized, Active Comparator Study of Oral-lyn™ Spray and Injected Human Insulin in Patients with Type-1 Diabetes Mellitus," will be undertaken at The Department of Endocrinology and Diabetes at the University Campus Bio-Medico in Rome, Italy under the supervision of internationally renowned diabetes investigator Professor Paolo Pozzilli, MD.
